Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection

Japanese Journal of Chemotherapy

Volumn 52, Issue 9, 2004, Pages 469-473

  Tanikaze, Naoko ^a   Komatsu, Masaru ^a   Shimakawa, Kouichi ^a   Yamamoto, Ikuyoshi ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

Arbekacin; AUC; Cmax; MIC; MRSA; PK PD

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; HABEKACIN; METICILLIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; RETROSPECTIVE STUDY;

EID: 6944222641     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Jacobs M R: Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 7: 589-596, 2001
2. Frimodt-Moller N: How predictive is PK/PD for antibacterial agents ? Int J Antimicrob Agents 19: 333-339, 2002
3. Nicolau D P: Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 9: 292-296, 2003
4. Lacy M K, Nicolau D P, Nightingale C H, et al: The pharmacodynamics of aminoglycosides. Clin Infect Dis 27: 23-27, 1998
5. National Committee for Clinical Laboratory Standards (NCCLS): Approved standard-Sixth Edition M7-A6, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS, Wayne, 2003
6. Mattie H, Craig W A, Pechere J C: Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 24: 281-293, 1989
7. Japanese source. Chemother 34: 41-57, 1986